Nautilus Biotechnology Inc Ordinary Shares NAUT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
-
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
-
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 164
- Website
- https://www.nautilus.bio
Comparables
Valuation
|
Metric
|
NAUT
|
CSTL
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 237.59 | 79.35 |
Price/Book Value | 1.40 | 1.86 | 58.79 |
Price/Sales | — | 2.74 | 20.56 |
Price/Cash Flow | — | 14.94 | 79.72 |
Price/Earnings
NAUT
CSTL
LLY
Financial Strength
|
Metric
|
NAUT
|
CSTL
|
LLY
|
|---|---|---|---|
Quick Ratio | 19.29 | 7.75 | 0.61 |
Current Ratio | 19.69 | 8.12 | 1.11 |
Interest Coverage | — | −54.71 | 15.08 |
Quick Ratio
NAUT
CSTL
LLY
Profitability
|
Metric
|
NAUT
|
CSTL
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | −18.82% | 7.97% | 13.15% |
Return on Equity (Normalized) | −21.67% | 9.08% | 69.16% |
Return on Invested Capital (Normalized) | −23.15% | 6.49% | 23.97% |
Return on Assets
NAUT
CSTL
LLY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ldvrvnxzy | Mlzrc | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yhldpqk | Wsrnfq | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zxlxgrdjc | Xjylfm | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qttbwryt | Ttvspt | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Qngnpbfx | Hcf | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wfbgzll | Jphx | $28.5 Bil | |||
| Moderna Inc
MRNA
| Plhyhqh | Shbx | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Vmkbwgjj | Nhmzr | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jjqyfnprd | Xxpdcnz | $13.0 Bil | |||
| Incyte Corp
INCY
| Ldzvvpgpk | Mnxytrq | $12.9 Bil |
United States